Drug Type Small molecule drug |
Synonyms Fursultiamine (JAN/INN), Thiamin tetrahydrofurfuryl disulfide, Thiamine tetrahydrofurfuryl disulfide + [7] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (02 May 1961), |
Regulation- |
Molecular FormulaC17H26N4O3S2 |
InChIKeyJTLXCMOFVBXEKD-UHFFFAOYSA-N |
CAS Registry804-30-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03319 | Fursultiamine |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Beriberi | Japan | 02 May 1961 | |
| Beriberi | Japan | 02 May 1961 | |
| Thiamine Deficiency | Japan | 02 May 1961 | |
| Thiamine Deficiency | Japan | 02 May 1961 | |
| Wernicke Encephalopathy | Japan | 02 May 1961 | |
| Wernicke Encephalopathy | Japan | 02 May 1961 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | United States | 29 Apr 2025 |





